CalciMedica has received approval from the FDA to proceed with a Phase 2 study of Auxora™ in treating severe cases of acute kidney injury.

Guaifenesin, approved for medical use in Japan in 1949, is an expectorant medication found in numerous over-the-counter products.

Artax has initiated the dosing of the inaugural participant in their Phase 2a clinical study for Psoriasis, assessing the effects of compound AX-158.

Ketorolac Tromethamine, or Toradol®, is an NSAID used to treat moderate to severe pain.

Otsuka Reveals Key Outcomes from Final Stage Trial of AVP-786 for Managing Alzheimer’s-Related Dementia Agitation.

Zyprexa® (Olanzapine), an antipsychotic, is commonly used to treat schizophrenia, bipolar 1, and related agitation.

Puma Biotechnology has launched a Phase II study for Alisertib, targeting Small Cell Lung Cancer, named ALISCA-Lung1.

Zelenirstat, an effective oral NMT inhibitor, showed promising results in treating advanced relapsed/refractory cancer at 2024's ASCO_GI.

Galderma declares submission approval of Nemolizumab for treating Prurigo Nodularis and Eczema in America and Europe.

Vesanoid, also known as Tretinoin, is a vitamin A derivative that has been given the green light for treating acne vulgaris and specific forms of promyelocytic leukemia.

Biogen Secures European Commission for New Drug SKYCLARYS® (omaveloxolone), Pioneering Treatment for Friedreich’s Ataxia.

Tinengotinib, a selective multi-kinase inhibitor, effectively targets FGFR2 fusion/rearrangement and resistance mutations in early trials involving cholangiocarcinoma patients.